Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, teriparatide (Forsteo®) cannot be endorsed for use within NHS Wales for the treatment of osteoporosis associated with glucocorticoid therapy in women and men at increased risk of fractures. |
||
|
||
Medicine details |
||
| Medicine name | teriparatide (Forsteo®) | |
| Formulation | 20 micrograms/80 microlitres solution for injection | |
| Reference number | 305 | |
| Indication | For the treatment of osteoporosis associated with glucocorticoid therapy in women and men at increased risk of fractures. |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 19/01/2009 | |